Cediranib In Patients With Relapsed Platinum-Sensitive Ovarian Cancer

Cediranib in patients with relapsed platinum-sensitive ovarian cancer

Cediranib, an oral antiangiogenic vascular endothelial growth factor receptor 1–3 inhibitor, can increase survival in women with recurrent ovarian cancer, according to a new study. Researchers assessed 456 women to test the treatment, which was successful when used in tandem with platinum-based chemotherapy. Three groups were established: Arm A, which received chemotherapy and placebo-only maintenance; arm B, which received cediranib and chemotherapy with placebo-only maintenance; and arm C, which received cediranib and chemotherapy along with cediranib daily for maintenance. The primary endpoint was progression-free survival between arms A and C. Ninety-six percent of women in arm A and 86% of women in arm C had disease progression at a median 19.5 months of follow-up. Median progression-free survival was 11 months in arm C, compared with 8.7 months in arm A. Arm B had 90% of patients experience disease progression with a median progression-free survival rate of 9.9 months. The researchers say the findings point to the benefits of adding cediranib to platinum-based chemotherapy, though they also note the “toxic effects of cediranib and other VEFR inhibitors can be problematic and need careful management.”

To read this article by Pharmacist.com, click here or to read the full text, click here.


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s